ATIM-08. A PHASE I TRIAL OF PEMBROLIZUMAB AND VORINOSTAT COMBINED WITH TEMOZOLOMIDE AND RADIATION THERAPY FOR NEWLY DIAGNOSED GLIOBLASTOMA (NCT03426891)

BACKGROUND: A growing body of evidence indicates that epigenetic silencing of genes involved in antigen processing and immune recognition results in immune escape and resistance to immunotherapy. Pre-clinical experiments have shown that use of histone deacetylases inhibitors such as vorinostat can r...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Neuro Oncol
Main Authors: Sahebjam, Solmaz, Forsyth, Peter, Tran, Nam, Mokhtari, Sepideh, Arrington, John, Jaglal, Michael, Etame, Arnold, Liu, James, Wicklund, Melissa, Gatewood, Tyra, Macaulay, Robert, Robinson, Timothy, Yu, Michael
Formato: Artigo
Idioma:Inglês
Publicado: Oxford University Press 2018
Assuntos:
Abstracts
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6216125/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.005
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares